RAD52 and pancreatic neoplasm: To evaluate the efficacy of the newly identified putative RAD52 inhibitors, we first treated patient-derived BRCA2-proficient (BxPC3) and BRCA2-deficient (Capan-1) pancreatic cancer cells (Figure 3).